OBJECTIVE: To determine whether tumour necrosis factor (TNF) gene polymorphisms and/or the shared epitope are genetic predictors of the response to adalimumab (ADA) in rheumatoid arthritis (RA). METHODS: This ancillary study to the Research in Active Rheumatoid Arthritis (ReAct) Phase IIIb study included a large cohort of Caucasian patients with RA from France (n = 388) treated with ADA plus methotrexate (MTX) (n = 182), ADA plus any other DMARD (n = 98) or ADA alone (n = 108). The primary outcome was ACR50 at 12 weeks. Patients underwent genotyping for HLA-DRB1 and three TNF gene polymorphisms (-238A/G,-308A/G and-857C/T). Extended haplotypes involving HLA-DRB1 and TNF loci were reconstructed using the PHASE program. RESULTS: A total of 151 patients (40%) had an ACR50 response at week 12. Neither the number of HLA-DRB1 shared epitope copies nor presence of the three TNF polymorphisms tested separately was significantly associated with ACR50 response at week 12. However, haplotype reconstruction of the TNF locus revealed that the GGC haplotype (-238G/-308G/-857C) in a homozygous form (i.e. present in more than half of the patients) was significantly associated with a lower ACR50 response to ADA at 12 weeks (34% vs. 50% in patients without the haplotype) (p = 0.003; pa = 0.015). This effect was more important in the subgroup of patients concomitantly treated with MTX. CONCLUSION: This large pharmacogenetic study provides preliminary data indicating that a single TNF locus haplotype (-238G/-308G/-857C), present on both chromosomes is associated with a lower response to ADA, mainly in patients treated with ADA and MTX.
OBJECTIVE: To determine whether tumour necrosis factor (TNF) gene polymorphisms and/or the shared epitope are genetic predictors of the response to adalimumab (ADA) in rheumatoid arthritis (RA). METHODS: This ancillary study to the Research in Active Rheumatoid Arthritis (ReAct) Phase IIIb study included a large cohort of Caucasian patients with RA from France (n = 388) treated with ADA plus methotrexate (MTX) (n = 182), ADA plus any other DMARD (n = 98) or ADA alone (n = 108). The primary outcome was ACR50 at 12 weeks. Patients underwent genotyping for HLA-DRB1 and three TNF gene polymorphisms (-238A/G,-308A/G and-857C/T). Extended haplotypes involving HLA-DRB1 and TNF loci were reconstructed using the PHASE program. RESULTS: A total of 151 patients (40%) had an ACR50 response at week 12. Neither the number of HLA-DRB1 shared epitope copies nor presence of the three TNF polymorphisms tested separately was significantly associated with ACR50 response at week 12. However, haplotype reconstruction of the TNF locus revealed that the GGC haplotype (-238G/-308G/-857C) in a homozygous form (i.e. present in more than half of the patients) was significantly associated with a lower ACR50 response to ADA at 12 weeks (34% vs. 50% in patients without the haplotype) (p = 0.003; pa = 0.015). This effect was more important in the subgroup of patients concomitantly treated with MTX. CONCLUSION: This large pharmacogenetic study provides preliminary data indicating that a single TNF locus haplotype (-238G/-308G/-857C), present on both chromosomes is associated with a lower response to ADA, mainly in patients treated with ADA and MTX.
Authors: S Mascheretti; J Hampe; T Kühbacher; H Herfarth; M Krawczak; U R Fölsch; S Schreiber Journal: Pharmacogenomics J Date: 2002 Impact factor: 3.550
Authors: G J Tang; S L Huang; H W Yien; W S Chen; C W Chi; C W Wu; W Y Lui; J H Chiu; T Y Lee Journal: Crit Care Med Date: 2000-08 Impact factor: 7.598
Authors: Alfonso Martinez; Marina Salido; Gema Bonilla; Dora Pascual-Salcedo; Miguel Fernandez-Arquero; Sonia de Miguel; Alejandro Balsa; Emilio G de la Concha; Benjamin Fernandez-Gutierrez Journal: Arthritis Rheum Date: 2004-04
Authors: Helen Fernandes; Baburao Koneru; Neil Fernandes; Meera Hameed; Marion C Cohen; Elizabeth Raveche; Stanley Cohen Journal: Transplantation Date: 2002-06-27 Impact factor: 4.939
Authors: L Padyukov; J Lampa; M Heimbürger; S Ernestam; T Cederholm; I Lundkvist; P Andersson; Y Hermansson; A Harju; L Klareskog; J Bratt Journal: Ann Rheum Dis Date: 2003-06 Impact factor: 19.103
Authors: Jennifer D Gorman; Raymond F Lum; John J Chen; Maria E Suarez-Almazor; Glenys Thomson; Lindsey A Criswell Journal: Arthritis Rheum Date: 2004-02
Authors: C A Wijbrandts; M G W Dijkgraaf; M C Kraan; M Vinkenoog; T J Smeets; H Dinant; K Vos; W F Lems; G J Wolbink; D Sijpkens; B A C Dijkmans; P P Tak Journal: Ann Rheum Dis Date: 2007-11-29 Impact factor: 19.103
Authors: Paula I Burgos; Maria I Danila; James M Kelley; Laura B Hughes; S Louis Bridges Journal: Ther Adv Musculoskelet Dis Date: 2009-04 Impact factor: 5.346
Authors: Miguel Cuchacovich; Daniel Bueno; Rodrigo Carvajal; Nicolás Bravo; Juan Carlos Aguillón; Diego Catalán; Lilian Soto Journal: Clin Rheumatol Date: 2014-08-02 Impact factor: 2.980
Authors: Olivia M Popa; Mihai Bojinca; Violeta Bojinca; Monica I Dutescu; Mihaela Meirosu; Ruxandra E Caisan; Claudia Ciofu; Constantin Bara; Luis O Popa Journal: Int J Mol Sci Date: 2011-08-08 Impact factor: 5.923
Authors: Jing Cui; Eli A Stahl; Saedis Saevarsdottir; Corinne Miceli; Dorothee Diogo; Gosia Trynka; Towfique Raj; Maša Umiċeviċ Mirkov; Helena Canhao; Katsunori Ikari; Chikashi Terao; Yukinori Okada; Sara Wedrén; Johan Askling; Hisashi Yamanaka; Shigeki Momohara; Atsuo Taniguchi; Koichiro Ohmura; Fumihiko Matsuda; Tsuneyo Mimori; Namrata Gupta; Manik Kuchroo; Ann W Morgan; John D Isaacs; Anthony G Wilson; Kimme L Hyrich; Marieke Herenius; Marieke E Doorenspleet; Paul-Peter Tak; J Bart A Crusius; Irene E van der Horst-Bruinsma; Gert Jan Wolbink; Piet L C M van Riel; Mart van de Laar; Henk-Jan Guchelaar; Nancy A Shadick; Cornelia F Allaart; Tom W J Huizinga; Rene E M Toes; Robert P Kimberly; S Louis Bridges; Lindsey A Criswell; Larry W Moreland; João Eurico Fonseca; Niek de Vries; Barbara E Stranger; Philip L De Jager; Soumya Raychaudhuri; Michael E Weinblatt; Peter K Gregersen; Xavier Mariette; Anne Barton; Leonid Padyukov; Marieke J H Coenen; Elizabeth W Karlson; Robert M Plenge Journal: PLoS Genet Date: 2013-03-28 Impact factor: 5.917